Filing Details
- Accession Number:
- 0001181431-13-017026
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2013-03-14 18:02:10
- Reporting Period:
- 2013-03-11
- Filing Date:
- 2013-03-14
- Accepted Time:
- 2013-03-14 18:02:10
- Original Submission Date:
- 2013-03-13
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1484478 | Furiex Pharmaceuticals Inc. | FURX | Pharmaceutical Preparations (2834) | 271197863 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1507502 | W Stephen Kaldor | C/O Furiex Pharmaceuticals, Inc. 3900 Paramount Parkway, Suite 150 Morrisville NC 27560 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-03-11 | 5,379 | $13.94 | 5,379 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-03-11 | 5,379 | $41.74 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2013-03-12 | 973 | $13.94 | 973 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-03-12 | 973 | $40.71 | 0 | No | 4 | S | Direct | |
Common Stock | Acquisiton | 2013-03-13 | 1,648 | $13.94 | 1,648 | No | 4 | M | Direct | |
Common Stock | Disposition | 2013-03-13 | 1,648 | $39.96 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (to buy) | Disposition | 2013-03-11 | 5,379 | $0.00 | 5,379 | $13.94 |
Common Stock | Stock Options (to buy) | Disposition | 2013-03-12 | 973 | $0.00 | 973 | $13.94 |
Common Stock | Stock Options (to buy) | Disposition | 2013-03-13 | 1,648 | $0.00 | 1,648 | $13.94 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
7,633 | 2021-05-19 | No | 4 | M | Direct | |
6,660 | 2021-05-19 | No | 4 | M | Direct | |
5,012 | 2021-05-19 | No | 4 | M | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Options (to buy) | $13.45 | 2021-10-12 | 8,825 | 8,825 | Direct | |
Common Stock | Stock Options (to buy) | $18.22 | 2022-05-24 | 17,500 | 17,500 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2021-10-12 | 8,825 | 8,825 | Direct |
2022-05-24 | 17,500 | 17,500 | Direct |
Footnotes
- These options and underlying shares were previously incorrectly reported as 8,000 in the Form 4.
- This exercise of options was previously incorrectly reported as being included in the 8,000 referenced in footnote (1).
- The options were awarded on 5/19/2011 and vest and become exercisable in full on the earlier of the first anniversary of the date of grant or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors.
- The options were awarded on 10/12/2011 and vest and become exercisable in full on the earlier of 5/19/2012 or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors.
- The options were awarded on 5/24/2012 and vest and become exercisable in full on the earlier of 5/24/2013 or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors.